Young-Rok Kim

Young-Rok Kim

Auto-generated profile, based on publicly available information

Young-Rok Kim


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DKDahyun Kim
Dahyun Kim
YKYoung-Rok Kim
Young-Rok Kim
HHHee-Jong Hwang
Hee-Jong Hwang
MCMarco A. Ciufolini
Marco A. Ciufolini
JLJusuk Lee
Jusuk Lee
JKJin-Hwan Kwak
Jin-Hwan Kwak
The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent bacterial threat. Yet, only two drugs, vancomycin and fidaxomicin, are approved by the FDA for the treatment of C. difficile infections as of this writing, while the global pipeline of new drugs is sparse at best. Thus, there is a clear and urgent need for new antibiotics against that organism. Herein, we disclose that AJ-024, a nitroimidazole derivative of a 26-membered thiopeptide, is a promising anti-C. difficile lead compound. Despite their unique mode of action, thiopeptides remain largely unexploited as anti-infective agents. AJ-024 combines potent in vitro activity against various strains of C. difficile with a noteworthy safety profile and desirable pharmacokinetic properties. Its time-kill kinetics against a hypervirulent C. difficile ribotype 027 and in vivo (mouse) efficacy compare favorably to vancomycin, and they define AJ-024 as a valuable platform for the development of new anti-C. difficile antibiotics.

29 September 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
SOSang-Hun Oh
Sang-Hun Oh
YKYoung-Rok Kim
Young-Rok Kim
Hee-Soo ParkHee-Soo Park
Hee-Soo Park
KOKyu-Man Oh
Kyu-Man Oh
YCYoung Lag Cho
Young Lag Cho
JKJin-Hwan Kwak
Jin-Hwan Kwak
Klebsiella pneumoniae is one of the important clinical organisms that causes various infectious diseases, including urinary tract infections, necrotizing pneumonia, and surgical wound infections. The increase in the incidence of multidrug-resistance K. pneumoniae is a major problem in public healthcare. Therefore, a novel antibacterial agent is needed to treat this pathogen. Here, we studied the in vitro and in vivo activities of a novel antibiotic LCB10-0200, a siderophore-conjugated cephalosporin, against clinical isolates of K. pneumoniae. In vitro susceptibility study found that LCB10-0200 showed potent antibacterial activity against K. pneumoniae, including the beta-lactamase producing strains. The in vivo efficacy of LCB10-0200 was examined in three different mouse infection models, including systemic, thigh, and urinary tract infections. LCB10-0200 showed more potent in vivo activity than ceftazidime in the three in vivo models against the drug-susceptible and drug-resistant K. pneumoniae strains. Taken together, these results show that LCB10-0200 is a potential antibacterial agent to treat infection caused by K. pneumoniae.

6 July 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
HCHa-Young Choi
Ha-Young Choi
BKBo-Min Kim
Bo-Min Kim
YKYoung-Rok Kim
Young-Rok Kim
TYTaehui Yang
Taehui Yang
SASunjoo Ahn
Sunjoo Ahn
WKWon Gon Kim
Won Gon Kim
Coralmycins, such as coralmycin A and DH-coralmycin A, have novel molecular skeletons and have been reported to exhibit potent antibacterial activity against standard Gram-positive bacterial strains. Here, the in vitro antibacterial activity against an extensive clinical isolate collection, time-kill kinetics, pharmacokinetics (PK), and in vivo efficacy of coralmycins were studied. Coralmycin A showed potent antibacterial activity with an MIC90 of 1 mg/L against 73 clinical methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci isolates, which was 2–8 times higher than the corresponding activities of DH-coralmycin A, vancomycin, daptomycin, and linezolid, and against 73 vancomycin-resistant Enterococcus and Streptococcus pneumoniae isolates, which was 4–16 times higher than the corresponding activities of DH-coralmycin A, daptomycin, and linezolid. Pharmacokinetic analysis after i.v. injection showed that coralmycins have a moderate volume of distribution and moderate-to-high clearance in mice. The coralmycin A and DH-coralmycin A bioavailability values were 61.3% and 11.7%, respectively, after s.c. administration. In a mouse respiratory tract infection model, coralmycin A showed bacteriostatic and bactericidal in vivo efficacies at an s.c. administration of 4 and 100 mg/kg bid, respectively; these efficacies were similar to those of vancomycin at 4 and 20 mg/kg bid, respectively. The present findings indicate that coralmycin A has great potential as a new class of antibiotic for treating infections caused by multidrug-resistant Gram-positive bacteria.

1 April 2019 in Desalination and Water Treatment
Verified
Journal Article
Open access
JPJi Hun Park
Ji Hun Park
SJSeul Jin
Seul Jin
YKYoung Rok Kim
Young Rok Kim
HDHyungki Do
Hyungki Do
CHCher-Won Hwang
Cher-Won Hwang